Abstract
Adrenergic receptor signaling and heart failure are inextricably linked. Beta-adrenergic receptors (β-ARs) serve not only as physiological modulators of heart rate and contractility, they are also primary therapeutic targets of individuals with heart failure as well as many other cardiovascular disorders. In light of these relationships, this short review will focus on the basic pharmacology distinguishing adrenergic receptor subtypes; on receptor subtype selective signaling; the molecular basis of β-AR gene expression; and, delve briefly into genetic variation of β-ARs that represents a potential basis of differential natural history of heart failure progression and that may serve as an underlying basis for therapeutic response.
Keywords: Adrenergic receptors, signaling, gene regulation, genetic variation, heart failure
Current Signal Transduction Therapy
Title:Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure
Volume: 7 Issue: 2
Author(s): J. David Port
Affiliation:
Keywords: Adrenergic receptors, signaling, gene regulation, genetic variation, heart failure
Abstract: Adrenergic receptor signaling and heart failure are inextricably linked. Beta-adrenergic receptors (β-ARs) serve not only as physiological modulators of heart rate and contractility, they are also primary therapeutic targets of individuals with heart failure as well as many other cardiovascular disorders. In light of these relationships, this short review will focus on the basic pharmacology distinguishing adrenergic receptor subtypes; on receptor subtype selective signaling; the molecular basis of β-AR gene expression; and, delve briefly into genetic variation of β-ARs that represents a potential basis of differential natural history of heart failure progression and that may serve as an underlying basis for therapeutic response.
Export Options
About this article
Cite this article as:
David Port J., Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure, Current Signal Transduction Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157436212800376645
DOI https://dx.doi.org/10.2174/157436212800376645 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Taking a Systems Approach to the Identification of Novel Therapeutic Targets and Biomarkers
Current Pharmaceutical Biotechnology The Role of Matrix Metalloproteinases in Essential Hypertension
Current Topics in Medicinal Chemistry Myocardial Infarction. Pathological Relevance and Relationship with Coronary Risk Factors
Current Pharmaceutical Design Nutritional Control, Gene Regulation, and Transformation of Vascular Smooth Muscle Cells in Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Ivabradine: A Current Overview
Current Clinical Pharmacology Adipose Tissue and Bone Marrow as Sources for Cell-based Therapeutic Angiogenesis in Ischemic Tissues: Biological Foundation and Clinical Prospects for Age-related Vascular Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Effectiveness and Safety of Digoxin on Chronic Heart Failure
Current Pharmaceutical Analysis Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know
Current Pharmaceutical Design Hyperhomocysteinemia and Endothelial Dysfunction
Current Hypertension Reviews Hypothyroidism and Endothelial Function: A Marker of Early Atherosclerosis?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Imaging of HER-2 Overexpression in Tumors for Guiding Therapy
Current Pharmaceutical Design Therapeutic Potential of Neuregulin in Cardiovascular System: Can we Ignore the Effects of Neuregulin on Electrophysiology?
Mini-Reviews in Medicinal Chemistry Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Polyphenols, Antioxidants and the Sympathetic Nervous System
Current Pharmaceutical Design Current Therapeutic Drugs Against Cerebral Vasospasm after Subarachnoid Hemorrhage: A Comprehensive Review of Basic and Clinical Studies
Current Drug Delivery Natriuretic Peptide Family: New Aspects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Platelets in Thrombosis and Hemostasis: Old Topic with New Mechanisms
Cardiovascular & Hematological Disorders-Drug Targets